Next Article in Journal
Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins
Next Article in Special Issue
Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
Previous Article in Journal
Anti-Inflammatory Drug Design Using a Molecular Hybridization Approach
Previous Article in Special Issue
Anticoagulation in the Elderly
Pharmaceuticals 2011, 4(11), 1475-1487; doi:10.3390/ph4111475
Review

Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees

Received: 13 September 2011; in revised form: 22 October 2011 / Accepted: 24 October 2011 / Published: 7 November 2011
(This article belongs to the Special Issue Anticoagulants)
View Full-Text   |   Download PDF [205 KB, uploaded 7 November 2011]
Abstract: This is a review of key factors for pharmacy and therapeutics committees to consider when developing a therapeutic interchange (TI) program for venous thromboembolism (VTE) prophylaxis. Recent patient safety initiatives aimed at reducing the incidence of hospital-acquired VTE may increase the prescribing of thromboprophylactic agents recommended in VTE management guidelines. As a result, more pharmacy and therapeutics committees may consider TI programs for parenteral anticoagulants. However, the TI of anticoagulants appears challenging at this time. Firstly, the therapeutic equivalence of the commonly prescribed parenteral anticoagulants, enoxaparin, dalteparin and fondaparinux, has not been established. Secondly, because of the wide range of clinical indications for these anticoagulants, a blanket agent-specific TI program could lead to off-label use. Use of an indication-specific TI program could be difficult to manage administratively, and may cause prescribing confusion and errors. Thirdly, careful dosing and contraindications of certain parenteral anticoagulants in special patient populations, such as those with renal impairment, further impact the suitability of these agents for inclusion in TI programs. Finally, although TI may appear to offer lower drug-acquisition costs, it is important to determine its effect on all cost parameters and ultimately ensure that the care of patients requiring VTE prophylaxis is not compromised.
Keywords: therapeutic interchange; anticoagulant; venous thromboembolism therapeutic interchange; anticoagulant; venous thromboembolism
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Amin, A. Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees. Pharmaceuticals 2011, 4, 1475-1487.

AMA Style

Amin A. Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees. Pharmaceuticals. 2011; 4(11):1475-1487.

Chicago/Turabian Style

Amin, Alpesh. 2011. "Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees." Pharmaceuticals 4, no. 11: 1475-1487.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert